ResMed | RMD - Assets


ResMed reported $8.78B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Ansell USD 3.33B 3.2M Dec/2025
Artivion USD 883.16M 1.64M Mar/2026
AtriCure USD 643.99M 10.19M Mar/2026
Baxter International USD 19.85B 209M Mar/2026
Cochlear AUD 2.79B 31.3M Dec/2025
Cooper Companies USD 12.48B 58.1M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Dexcom USD 6.63B 293.4M Mar/2026
Edwards Lifesciences USD 13.32B 376M Mar/2026
Fisher Paykel Healthcare NZD 2.63B 80.5M Dec/2025
Globus Medical USD 5.44B 136.79M Mar/2026
Haemonetics USD 2.4B 94.96M Mar/2026
Idexx Laboratories USD 3.39B 34.74M Mar/2026
Inogen USD 307.01M 5.03M Sep/2025
Insulet USD 2.99B 203.2M Mar/2026
Integra LifeSciences USD 3.58B 24.28M Mar/2026
Intuitive Surgical USD 20.11B 347.7M Mar/2026
Masimo USD 1.64B 56.2M Mar/2026
Medtronic USD 91.48B 139M Dec/2025
Philips EUR 27.27B 322M Mar/2026
Ramsay Health Care AUD 21.7B 777.8M Dec/2025
ResMed USD 8.78B 280.91M Mar/2026
Sigma Healthcare AUD 8.29B 6.91B Dec/2025
Sonic Healthcare AUD 15.38B 550.57M Dec/2024
Steris USD 10.74B 145.8M Mar/2026
Teleflex USD 6.78B 164.24M Mar/2026
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026